Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
NOT_YET_RECRUITING
Total Enrollment
500 participants
Study Classification
OBSERVATIONAL
Study Start Date
2025-05-01
Study Completion Date
2035-05-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The number of long-term lung cancer (LC) survivors increases, however many patients are diagnosed with recurrent or new thoracic cancers. High-dose reirradiation (reRT) is promising but associated with high severe toxicity rates. Existing studies are small lacking high-quality data, with no clear correlation between toxicity risk and delivered radiotherapy (RT) dose.
This Danish multicentre prospective cohort study aims to provide a framework for collecting radiotherapy-related toxicity data, loco-regional control, and overall survival data for patients with thoracic cancer undergoing reirradiation; with the ultimate aim of providing safe reirradiation to more patients.
As a secondary aim, guidelines for dose accumulation and provisional constraints for the organs at risk will be used to establish a uniform treatment strategy for reirradiation.
The CURE Lung trial will provide high-impact, globally missing data. This project will ensure full utilization of and learning from the trial, adding SDM, PROMs, and modality referral to the trial. It will model the correlation between toxicity burden and doses, enabling individualized reRT with optimized dose prescription based on toxicity risk and patient preferences, and assisting in the decision-making on the prescription dose and optimal modality. This will ensure safe reRT for the increasing number of long-term LC survivors.
This Danish multicentre prospective cohort study aims to provide a framework for collecting radiotherapy-related toxicity data, loco-regional control, and overall survival data for patients with thoracic cancer undergoing reirradiation; with the ultimate aim of providing safe reirradiation to more patients.
As a secondary aim, guidelines for dose accumulation and provisional constraints for the organs at risk will be used to establish a uniform treatment strategy for reirradiation.
The CURE Lung trial will provide high-impact, globally missing data. This project will ensure full utilization of and learning from the trial, adding SDM, PROMs, and modality referral to the trial. It will model the correlation between toxicity burden and doses, enabling individualized reRT with optimized dose prescription based on toxicity risk and patient preferences, and assisting in the decision-making on the prescription dose and optimal modality. This will ensure safe reRT for the increasing number of long-term LC survivors.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC
NCT03742687
Stage III Non-small-cell Lung Cancer
Stage IV Non-small Cell Lung Cancer
Radiotherapy Side Effect
RECRUITING
NA
Registry Study of Thoracic Reirradiation for Non-Small Cell Lung Cancer (NSCLC) Utilizing Proton Beam Therapy or Intensity Modulated Radiation Therapy
NCT01808677
Non-Small Cell Lung Cancer
COMPLETED
Reirradiation Dose Escalation in Thoracic Cancers
NCT06558175
Thoracic Cancer
Lung Cancer
Esophageal Cancer
NOT_YET_RECRUITING
PHASE1
Cardiopulmonary Toxicity of Thoracic Radiotherapy
NCT03978377
Oesophageal Cancer
Non Small Cell Lung Cancer
RECRUITING
Proton Beam Re-Irradiation in Thoracic Cancers
NCT02204761
Metastatic Malignant Neoplasm in the Lung
Recurrent Disease
Thoracic Neoplasm
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. BACKGROUND:
The number of long-term survivors is increasing for thoracic cancers, however, a significant proportion of lung cancer (LC) patients treated with curatively intended radiotherapy (RT) may experience locoregional recurrence or develop a new cancer. This highlights the need for effective local treatment options. Repeated high-dose RT (reRT) is a promising approach gaining traction in clinical practice. At Aarhus University Hospital (AUH), the fraction of LC patients offered curative reRT has increased from 4% in 2015 to 13% in 2024. The overall survival (OS) of reirradiated recurrent or new LC range from 7-14 months (from time of reirradiation) and depends on a variety of parameters, including tumour dose and PTV volume. ReRT has been linked to high rates of severe toxicity, leading to some patients not being offered curative reRT. Establishing solid evidence of the risks associated with reRT is crucial to offering these patients reRT on an equal footing with patients treated for their first cancer. Former studies on reRT of LC include a median of 40 (maximum 102) patients16, with diverse results on OS and no clear correlations between toxicity risk and cumulative (summed) RT doses.
2. AIM:
Establish a framework for LC reRT based on data from CURE Lung to support clinical and shared decision-making (SDM). Four sub-studies obtain this:
2.1 Establish a national infrastructure for reRT and implement decision-making tools to guide patient referrals to specialised modalities like proton therapy and MR-linac, ensuring optimal treatment modality selection to reRT for the individual patient.
2.2 Integrate and analyse Patient Reported Outcome Measures (PROM), Quality of Life (QoL), and decision regret data in CURE Lung. Mapping of the patient's self-reported symptoms and correlation to toxicity data ensures an optimal overview of total disease burden and informs which patients are candidates for reRT.
2.3 Establish and evaluate SDM focusing on the clinical risk assessment and the patient's wishes as tools for optimal patient involvement. SDM will improve the participants' knowledge, and accuracy of risk perceptions, and help them choose the best treatment, minimizing regret and improving QoL.
2.4 Build models correlating patient- and physician-reported toxicity to RT doses, considering prior treatments, co-morbidity, and QoL to inform decision-making. This will provide dose limits for reRT, allowing individualised dose prescriptions based on toxicity risk, comorbidities and prior treatments.
3. HYPOTHESES:
Primary hypothesis:
\- Cumulative radiation dose is related to radiotherapy-related toxicity for patients undergoing thoracic reirradiation
Secondary hypothesis:
\- Curative reirradiation is feasible and safe for a selected patient cohort when delivered based on strict dose limits
4. PATIENTS:
Recurrent or new LC, or solitary oligo lung metastases. The investigators plan for 500 patients in 3-4 years. Annually, approximately 100-150 patients are expected from the seven Danish RT centres based on a recent comprehensive national audit of RT retreatment numbers and sites.
5. TRIAL DESIGN AND DATA COLLECTION:
This is a multicentre prospective registration protocol.
The trial is based on a high mandatory standard being mandatory for participation with 1) 3D dose summation, 2) data on previous RT, systemic treatments, surgery, comorbidity and G3-4 thoracic toxicity collected at baseline, 3) prospective clinical follow-up with G2-5 toxicity scoring, and thoracic CT-imaging, performed every three months until two years and bi-annually until five years enabling reliable longitudinal toxicity scoring, and 4) pre-trial QA consisting of image registration, treatment planning and healthy tissue delineation.
Toxicity and patient-reported outcomes (PROM) will be monitored during and up to 5 years after treatment using common terminology criteria for adverse events (CTCAE) and the European Organisation for Research and Treatment of Cancer (EORTC) QoL questionnaires (QLQ-C30 and LC13). Central databases will be used for clinical (Redcap) and dosimetric (dcmcollab) data collection.
6. PERSPECTIVES:
The CURE Lung trial will yield internationally high-impact results. The trial is based on state-of-the-art treatment delivery, dose accumulation, and clinical data collection, ensuring exceptional data quality for modelling studies. The trial data will be unique in patient numbers and data quality. Similar data are not available Worldwide. The current project will ensure full utilisation of and learning from the trial, adding SDM, PROMs, referral to specialised modalities, and high-level QA to the trial. It will enable modelling the correlation between toxicity burden and individual patient doses, paving the way for individualised reRT with optimised dose prescription based on toxicity risk and patient preferences, and assisting in the decision-making on the prescription dose and optimal modality. This will ensure safe reRT for the increasing number of long-term LC survivors.
Results will be published in scientific international journals (Radiother Oncol, Int J Radiat Oncol Biol Phys, J Clin Oncol, and J Thorac Oncol), and presented at international conferences and Danske Kræftforskningsdage.
The findings may apply to reRT for other cancers, benefitting all Danish patients. The project underpins the new work package for reRT under the Danish Comprehensive Cancer Center for RT (DCCC-RT), aiming to collect and standardize national reRT data.
The number of long-term survivors is increasing for thoracic cancers, however, a significant proportion of lung cancer (LC) patients treated with curatively intended radiotherapy (RT) may experience locoregional recurrence or develop a new cancer. This highlights the need for effective local treatment options. Repeated high-dose RT (reRT) is a promising approach gaining traction in clinical practice. At Aarhus University Hospital (AUH), the fraction of LC patients offered curative reRT has increased from 4% in 2015 to 13% in 2024. The overall survival (OS) of reirradiated recurrent or new LC range from 7-14 months (from time of reirradiation) and depends on a variety of parameters, including tumour dose and PTV volume. ReRT has been linked to high rates of severe toxicity, leading to some patients not being offered curative reRT. Establishing solid evidence of the risks associated with reRT is crucial to offering these patients reRT on an equal footing with patients treated for their first cancer. Former studies on reRT of LC include a median of 40 (maximum 102) patients16, with diverse results on OS and no clear correlations between toxicity risk and cumulative (summed) RT doses.
2. AIM:
Establish a framework for LC reRT based on data from CURE Lung to support clinical and shared decision-making (SDM). Four sub-studies obtain this:
2.1 Establish a national infrastructure for reRT and implement decision-making tools to guide patient referrals to specialised modalities like proton therapy and MR-linac, ensuring optimal treatment modality selection to reRT for the individual patient.
2.2 Integrate and analyse Patient Reported Outcome Measures (PROM), Quality of Life (QoL), and decision regret data in CURE Lung. Mapping of the patient's self-reported symptoms and correlation to toxicity data ensures an optimal overview of total disease burden and informs which patients are candidates for reRT.
2.3 Establish and evaluate SDM focusing on the clinical risk assessment and the patient's wishes as tools for optimal patient involvement. SDM will improve the participants' knowledge, and accuracy of risk perceptions, and help them choose the best treatment, minimizing regret and improving QoL.
2.4 Build models correlating patient- and physician-reported toxicity to RT doses, considering prior treatments, co-morbidity, and QoL to inform decision-making. This will provide dose limits for reRT, allowing individualised dose prescriptions based on toxicity risk, comorbidities and prior treatments.
3. HYPOTHESES:
Primary hypothesis:
\- Cumulative radiation dose is related to radiotherapy-related toxicity for patients undergoing thoracic reirradiation
Secondary hypothesis:
\- Curative reirradiation is feasible and safe for a selected patient cohort when delivered based on strict dose limits
4. PATIENTS:
Recurrent or new LC, or solitary oligo lung metastases. The investigators plan for 500 patients in 3-4 years. Annually, approximately 100-150 patients are expected from the seven Danish RT centres based on a recent comprehensive national audit of RT retreatment numbers and sites.
5. TRIAL DESIGN AND DATA COLLECTION:
This is a multicentre prospective registration protocol.
The trial is based on a high mandatory standard being mandatory for participation with 1) 3D dose summation, 2) data on previous RT, systemic treatments, surgery, comorbidity and G3-4 thoracic toxicity collected at baseline, 3) prospective clinical follow-up with G2-5 toxicity scoring, and thoracic CT-imaging, performed every three months until two years and bi-annually until five years enabling reliable longitudinal toxicity scoring, and 4) pre-trial QA consisting of image registration, treatment planning and healthy tissue delineation.
Toxicity and patient-reported outcomes (PROM) will be monitored during and up to 5 years after treatment using common terminology criteria for adverse events (CTCAE) and the European Organisation for Research and Treatment of Cancer (EORTC) QoL questionnaires (QLQ-C30 and LC13). Central databases will be used for clinical (Redcap) and dosimetric (dcmcollab) data collection.
6. PERSPECTIVES:
The CURE Lung trial will yield internationally high-impact results. The trial is based on state-of-the-art treatment delivery, dose accumulation, and clinical data collection, ensuring exceptional data quality for modelling studies. The trial data will be unique in patient numbers and data quality. Similar data are not available Worldwide. The current project will ensure full utilisation of and learning from the trial, adding SDM, PROMs, referral to specialised modalities, and high-level QA to the trial. It will enable modelling the correlation between toxicity burden and individual patient doses, paving the way for individualised reRT with optimised dose prescription based on toxicity risk and patient preferences, and assisting in the decision-making on the prescription dose and optimal modality. This will ensure safe reRT for the increasing number of long-term LC survivors.
Results will be published in scientific international journals (Radiother Oncol, Int J Radiat Oncol Biol Phys, J Clin Oncol, and J Thorac Oncol), and presented at international conferences and Danske Kræftforskningsdage.
The findings may apply to reRT for other cancers, benefitting all Danish patients. The project underpins the new work package for reRT under the Danish Comprehensive Cancer Center for RT (DCCC-RT), aiming to collect and standardize national reRT data.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Radiotherapy Side Effect
Radiation Toxicity
Oncology
Lung Cancer
Thoracic Cancer
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with thoracic cancer elegible for reirradation.
Recurrent lung cancer, new primary lung cancer, solitary lung metastasis
Radiotherapy
Intervention Type
RADIATION
Radiotherapy is offered in the same dose to all patients eligible to reirradiation no matter if they are enrolled in the study or not. Meaning no intervention is done. This is a registration study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Radiotherapy
Radiotherapy is offered in the same dose to all patients eligible to reirradiation no matter if they are enrolled in the study or not. Meaning no intervention is done. This is a registration study.
Intervention Type
RADIATION
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Radiotherapy of thoracic lesion(s) (loco-regional lung cancer recurrence, new primary lung cancer, or solitary oligo metastasis) with the aim of long-term local control.
* Reirradiation type 1 or type 2, i.e. previous radiotherapy to the thorax as per ESTRO-EORTC consensus definition of reirradiation \[Andratschke 2022\]. For the sake of this study, multiple treatments to the lungs will be classified as type 2 reirradiation.
* Verification of malignancy based on biopsy. If no biopsy is available, the decision of reirradiation should be agreed upon in a multidisciplinary conference.
* Available digital dose plan(s) from former radiotherapy course(s) (DICOM files) - note that multiple re-treatments are allowed.
* Adequate lung function to tolerate treatment, at the discretion of the treating physician.
* Ability to complete a radiotherapy course with the aim of local control.
* ECOG Performance status 0-2.
* Estimated life expectancy ≥ 6 months
* Age ≥18 years
* Signed informed consent
* Reirradiation type 1 or type 2, i.e. previous radiotherapy to the thorax as per ESTRO-EORTC consensus definition of reirradiation \[Andratschke 2022\]. For the sake of this study, multiple treatments to the lungs will be classified as type 2 reirradiation.
* Verification of malignancy based on biopsy. If no biopsy is available, the decision of reirradiation should be agreed upon in a multidisciplinary conference.
* Available digital dose plan(s) from former radiotherapy course(s) (DICOM files) - note that multiple re-treatments are allowed.
* Adequate lung function to tolerate treatment, at the discretion of the treating physician.
* Ability to complete a radiotherapy course with the aim of local control.
* ECOG Performance status 0-2.
* Estimated life expectancy ≥ 6 months
* Age ≥18 years
* Signed informed consent
Exclusion Criteria
* Uncontrolled other malignancy.
* The primary and the reirradiation treatment may not be quasi-simultaneous (i.e. the two treatments should be planned independently)
* Pregnancy
* Radiotherapy to a minimum CTV mean dose of 45 Gy for SCLC and 50 Gy for NSCLC and oligometastatic lesions. Treatment schedule according to local protocols and treating physician preference.
* The primary and the reirradiation treatment may not be quasi-simultaneous (i.e. the two treatments should be planned independently)
* Pregnancy
* Radiotherapy to a minimum CTV mean dose of 45 Gy for SCLC and 50 Gy for NSCLC and oligometastatic lesions. Treatment schedule according to local protocols and treating physician preference.
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Aarhus
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365-76. doi: 10.1093/jnci/85.5.365.
Reference Type
BACKGROUND
Abusaris H, Storchi PR, Brandwijk RP, Nuyttens JJ. Second re-irradiation: efficacy, dose and toxicity in patients who received three courses of radiotherapy with overlapping fields. Radiother Oncol. 2011 May;99(2):235-9. doi: 10.1016/j.radonc.2011.03.010. Epub 2011 Apr 15.
Reference Type
BACKGROUND
Amini A, Yang J, Williamson R, McBurney ML, Erasmus J Jr, Allen PK, Karhade M, Komaki R, Liao Z, Gomez D, Cox J, Dong L, Welsh J. Dose constraints to prevent radiation-induced brachial plexopathy in patients treated for lung cancer. Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):e391-8. doi: 10.1016/j.ijrobp.2011.06.1961.
Reference Type
BACKGROUND
Andratschke N, Willmann J, Appelt AL, Alyamani N, Balermpas P, Baumert BG, Hurkmans C, Hoyer M, Langendijk JA, Kaidar-Person O, van der Linden Y, Meattini I, Niyazi M, Reynaert N, De Ruysscher D, Tanadini-Lang S, Hoskin P, Poortmans P, Nieder C. European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus on re-irradiation: definition, reporting, and clinical decision making. Lancet Oncol. 2022 Oct;23(10):e469-e478. doi: 10.1016/S1470-2045(22)00447-8.
Reference Type
BACKGROUND
Ang KK, Price RE, Stephens LC, Jiang GL, Feng Y, Schultheiss TE, Peters LJ. The tolerance of primate spinal cord to re-irradiation. Int J Radiat Oncol Biol Phys. 1993 Feb 15;25(3):459-64. doi: 10.1016/0360-3016(93)90067-6.
Reference Type
BACKGROUND
Ang KK, Jiang GL, Feng Y, Stephens LC, Tucker SL, Price RE. Extent and kinetics of recovery of occult spinal cord injury. Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):1013-20. doi: 10.1016/s0360-3016(01)01599-1.
Reference Type
BACKGROUND
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeno J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Ozguroglu M; PACIFIC Investigators. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017 Nov 16;377(20):1919-1929. doi: 10.1056/NEJMoa1709937. Epub 2017 Sep 8.
Reference Type
BACKGROUND
Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeno J, Faivre-Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada M, Dennis PA, Ozguroglu M; PACIFIC Investigators. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018 Dec 13;379(24):2342-2350. doi: 10.1056/NEJMoa1809697. Epub 2018 Sep 25.
Reference Type
BACKGROUND
Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Paulus R, Yamanaka T, Bozonnat MC, Uitterhoeve A, Wang X, Stewart L, Arriagada R, Burdett S, Pignon JP. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010 May 1;28(13):2181-90. doi: 10.1200/JCO.2009.26.2543. Epub 2010 Mar 29.
Reference Type
BACKGROUND
Badiyan SN, Rutenberg MS, Hoppe BS, Mohindra P, Larson G, Hartsell WF, Tsai H, Zeng J, Rengan R, Glass E, Katz S, Vargas C, Feigenberg SJ, Simone CB 2nd. Clinical Outcomes of Patients With Recurrent Lung Cancer Reirradiated With Proton Therapy on the Proton Collaborative Group and University of Florida Proton Therapy Institute Prospective Registry Studies. Pract Radiat Oncol. 2019 Jul-Aug;9(4):280-288. doi: 10.1016/j.prro.2019.02.008. Epub 2019 Feb 23.
Reference Type
BACKGROUND
Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris MG, Scher HI, Schrag D. Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol. 2006 Nov;7(11):903-9. doi: 10.1016/S1470-2045(06)70910-X.
Reference Type
BACKGROUND
Basch E. The missing voice of patients in drug-safety reporting. N Engl J Med. 2010 Mar 11;362(10):865-9. doi: 10.1056/NEJMp0911494. No abstract available.
Reference Type
BACKGROUND
Becerra Perez MM, Menear M, Brehaut JC, Legare F. Extent and Predictors of Decision Regret about Health Care Decisions: A Systematic Review. Med Decis Making. 2016 Aug;36(6):777-90. doi: 10.1177/0272989X16636113. Epub 2016 Mar 14.
Reference Type
BACKGROUND
Bellera CA, Rainfray M, Mathoulin-Pelissier S, Mertens C, Delva F, Fonck M, Soubeyran PL. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol. 2012 Aug;23(8):2166-2172. doi: 10.1093/annonc/mdr587. Epub 2012 Jan 16.
Reference Type
BACKGROUND
Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer. 1994;30A(5):635-42. doi: 10.1016/0959-8049(94)90535-5.
Reference Type
BACKGROUND
Bertelsen AS, Schytte T, Moller PK, Mahmood F, Riis HL, Gottlieb KL, Agergaard SN, Dysager L, Hansen O, Gornitzka J, Veldhuizen E, ODwyer DB, Christiansen RL, Nielsen M, Jensen HR, Brink C, Bernchou U. First clinical experiences with a high field 1.5 T MR linac. Acta Oncol. 2019 Oct;58(10):1352-1357. doi: 10.1080/0284186X.2019.1627417. Epub 2019 Jun 26.
Reference Type
BACKGROUND
Binkley MS, Hiniker SM, Chaudhuri A, Maxim PG, Diehn M, Loo BW Jr, Shultz DB. Dosimetric Factors and Toxicity in Highly Conformal Thoracic Reirradiation. Int J Radiat Oncol Biol Phys. 2016 Mar 15;94(4):808-15. doi: 10.1016/j.ijrobp.2015.12.007. Epub 2015 Dec 17.
Reference Type
BACKGROUND
Bjordal K, de Graeff A, Fayers PM, Hammerlid E, van Pottelsberghe C, Curran D, Ahlner-Elmqvist M, Maher EJ, Meyza JW, Bredart A, Soderholm AL, Arraras JJ, Feine JS, Abendstein H, Morton RP, Pignon T, Huguenin P, Bottomly A, Kaasa S. A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. EORTC Quality of Life Group. Eur J Cancer. 2000 Sep;36(14):1796-807. doi: 10.1016/s0959-8049(00)00186-6.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
R374-A22286
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
Curelung2025
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Repeat CT for Evaluation of Inter- and Intrafraction Changes During Curative Thoracic Radiotherapy
NCT03024138
COMPLETED
Stereotactic Volumetric Radiotherapy in Prostate Cancer
NCT02423889
COMPLETED
PHASE2
Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC
NCT05548504
NOT_YET_RECRUITING
PHASE2
Trial Comparing Two Protocols of re Irradiation in an Irradiated Area for Carcinoma of the Upper Aerodigestive Tract
NCT01211938
COMPLETED
PHASE2/PHASE3
Moderate Hypofractionated Radiotherapy for Lung Cancer
NCT03833193
UNKNOWN
NA
Once Daily Accelerated Fractionation With Concomitant Boost to the Gross Tumor Volume Compared With Twice Daily Hyperfractionation in Concurrent Chemoradiation in Patients With Limited Disease Small Cell Lung Cancer
NCT01710956
UNKNOWN
PHASE2
Partial Volume High-Dose Irradiation in Renal Cell Carcinoma for Intra-TUmoural Control ALongside Current Management
NCT06995664
RECRUITING
NA
Thoracal Radiotherapy and Tarceva
NCT02714530
TERMINATED
PHASE2
Postoperative Radiotherapy of Non-small Cell Lung Cancer: Accelerated vs. Conventional Fractionation
NCT02189967
COMPLETED
NA
Remote Monitoring of Patient Reported Outcomes to Improve the Efficacy of the Acute Phase Radiotherapy Review Process
NCT06274892
RECRUITING
NA
Improving Quality of Life and Function for Older Cancer Patients Receiving Radiotherapy
NCT03071640
COMPLETED
Analysis of Treatment Outcome and Toxicity in Non-small Cell Lung Cancer Patients Wither-irradiated to a High Dose for Recurrent Disease
NCT01941303
COMPLETED
Safety and Efficacy of SBRT in the Reirradiation for Ultra-central Thoracic Malignant Tumors
NCT05189054
RECRUITING
Prospective Study on Factors Predicting Chemo-Radiotherapy Induced Pulmonary and Esophageal Injury
NCT00631839
UNKNOWN
Distributed Learning of Edic and CardIac Dose Effects in Lung Cancer
NCT06329648
NOT_YET_RECRUITING
Tarceva And Radiotherapy in Locally Advanced Lung Cancer Non-small Cell Lung Cancer
NCT00888511
COMPLETED
PHASE2
3-Dimensional Conformal Radiation Therapy Versus Intensity Modulated Radiation Therapy
NCT00520702
COMPLETED
PHASE2
A Trial to Evaluate the Improvement in Lung Cancer Patients Receiving Radiation With or Without Brachytherapy
NCT01351116
COMPLETED
PHASE3
Hypofractionated Radiation Therapy to Improve Immunotherapy Response in Non-Small Cell Lung Cancer
NCT03035890
COMPLETED
NA
Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response
NCT06831032
NOT_YET_RECRUITING
NA
Coagulation System In STereotactic Radiotherapy Of NSCLC
NCT03893461
UNKNOWN
Ventilation Using Radiographic Examination: Functional Lung Imaging Techniques for the Reduction of Toxicity in Functional Avoidance Radiation Therapy
NCT06159660
NOT_YET_RECRUITING
Tarceva With Whole Brain Radiation Therapy - Brain Mets From Non-Small Cell Lung Cancer
NCT00871923
COMPLETED
PHASE2
4D Cone Beam CT Reconstruction for Radiotherapy Via Motion Vector Optimization
NCT03551405
TERMINATED
Predicting Cell Death by Radiation Therapy in Early Stage Non-small Cell Lung Cancer: a Prospective Translational Trial
NCT01138722
TERMINATED
PHASE2